Aastrom Biosciences' CEO to Present at The Morgan Stanley Small Cap Executive Conference
June 10 2005 - 8:00AM
PR Newswire (US)
Aastrom Biosciences' CEO to Present at The Morgan Stanley Small Cap
Executive Conference ANN ARBOR, Mich., June 10
/PRNewswire-FirstCall/ -- Aastrom Biosciences, Inc. (NASDAQ:ASTM)
today announced that R. Douglas Armstrong, Ph.D., Chief Executive
Officer and Chairman, will present at the Morgan Stanley Small Cap
Executive Conference. The conference will be held June 13-15th, at
the Ritz- Carlton Hotel, Battery Park in New York City. Dr.
Armstrong will present in the Manhattan A Room at 9:30 a.m.
(Eastern Time) on Wednesday, June 15th. Morgan Stanley is a global
financial services firm and a market leader in securities,
investment management, and credit services. With more than 600
offices in 28 countries, Morgan Stanley connects people, ideas and
capital to help clients achieve their financial aspirations. A live
webcast of Dr. Armstrong's presentation can be accessed by logging
onto the web at
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ASTM&item_id=1068241.
An archived replay of the presentation will also be available for
90 days after the conference, at the same site. About Aastrom
Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM) is
developing patient-specific products for the repair or regeneration
of human tissues, utilizing the Company's proprietary adult stem
cell technology. Aastrom's strategic position in the tissue
regeneration sector is enabled by its proprietary Tissue Repair
Cells (TRCs), a mix of bone marrow-derived adult stem and
progenitor cells, and the AastromReplicell(R) System, an
industry-unique automated cell production platform used to produce
cells for clinical use. TRCs are the core component of the products
Aastrom is developing for severe bone fractures, ischemic vascular
disease, jaw reconstruction and spine fusion, with Phase I/II level
clinical trials active in the U.S. and EU for some of these
indications. For more information, visit Aastrom's website at
http://www.aastrom.com/. This document contains forward-looking
statements, including without limitation, statements concerning
planned clinical trials, product development objectives, potential
advantages of TRCs and the AastromReplicell(R) System, and
potential product applications, which involve certain risks and
uncertainties. The forward-looking statements are also identified
through use of the words "planned," and other words of similar
meaning. Actual results may differ significantly from the
expectations contained in the forward- looking statements. Among
the factors that may result in differences are potential patient
accrual difficulties, clinical trial results, potential product
development difficulties, the effects of competitive therapies,
regulatory approval requirements, the availability of financial and
other resources and the allocation of resources among different
potential uses. These and other significant factors are discussed
in greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly or Cameron Associates Becky Anderson Kevin McGrath --
Institutions Investor Relations Department Phone: (212) 245-4577
Aastrom Biosciences, Inc. Alyson Nikulicz -- Media Phone: (734)
930-5777 Phone: (212) 554-5464 DATASOURCE: Aastrom Biosciences,
Inc. CONTACT: Kris M. Maly or Becky Anderson, Investor Relations
Department of Aastrom Biosciences, Inc., +1-734-930-5777; or Kevin
McGrath -- Institutions, +1-212-245-4577, or Alyson Nikulicz --
Media, +1-212-554-5464 both of Cameron Associates Web site:
http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024